NASDAQ:CDLX - Cardlytics Stock Price, Forecast & News

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Cardlytics Inc (NASDAQ:CDLX) issued its quarterly earnings data on Tuesday, November, 12th. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.31. The company earned $56.42 million during the quarter, compared to analyst estimates of $50.02 million. Cardlytics had a negative return on equity of 44.53% and a negative net margin of 17.01%. Cardlytics's revenue was up 63.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.15) earnings per share. View Cardlytics' Earnings History.

Cardlytics is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Cardlytics.

Cardlytics issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $68.5-69.5 million, compared to the consensus revenue estimate of $59 million.

7 brokerages have issued 1-year price objectives for Cardlytics' shares. Their forecasts range from $26.00 to $100.00. On average, they expect Cardlytics' stock price to reach $62.00 in the next year. This suggests that the stock has a possible downside of 25.3%. View Analyst Price Targets for Cardlytics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardlytics.

Media headlines about CDLX stock have trended positive on Friday, InfoTrie reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cardlytics earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Cardlytics.

Some companies that are related to Cardlytics include Stars Group (TSG), Wix.Com (WIX), InterXion (INXN), GDS (GDS), Sabre (SABR), HUYA (HUYA), Tripadvisor (TRIP), Medallia (MDLA), Switch (SWCH), Livongo Health (LVGO), DouYu International (DOYU), Pluralsight (PS), SVMK (SVMK), Eventbrite (EB) and Health Catalyst (HCAT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Caterpillar (CAT), Alibaba Group (BABA), Okta (OKTA), Trade Desk (TTD), Range Resources (RRC), Shopify (SHOP), Square (SQ), Store Capital (STOR), Coupa Software (COUP) and Nutanix (NTNX).

(CDLX) raised $76 million in an initial public offering (IPO) on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Calamos Advisors LLC (0.24%). Company insiders that own Cardlytics stock include Aimia Inc, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman. View Institutional Ownership Trends for Cardlytics.

CDLX stock was bought by a variety of institutional investors in the last quarter, including Calamos Advisors LLC. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, David Thomas Evans and Scott D Grimes. View Insider Buying and Selling for Cardlytics.

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CDLX stock can currently be purchased for approximately $82.99.

Cardlytics has a market capitalization of $1.89 billion and generates $150.68 million in revenue each year. The company earns $-53,040,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. View Additional Information About Cardlytics.

The official website for Cardlytics is http://www.cardlytics.com/.

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]